Imagine the hair follicle as a small factory on a strict schedule: grow (anagen), rest (telogen), grow again. In androgenetic alopecia (AGA), that schedule falls apart: growth phases shorten, rest drags on, and the follicle miniaturizes with each cycle — hair thins, lightens, and eventually disappears [1].

AGA is the most common cause of hair loss worldwide, increasingly debuting at a young age, and for many it is more than a cosmetic flaw, taking a toll on self-esteem and quality of life [1]. The FDA has approved only minoxidil and finasteride, and neither works for everyone: minoxidil depends on individual sulfotransferase activity and can cause contact dermatitis, while finasteride is limited by sexual dysfunction risk and safety concerns when pregnancy is planned [1]. Hence the interest in new strategies, including exosomes.

In a review (International Journal of Nanomedicine, August 2026), Chen and coauthors compiled the published evidence on exosomes in AGA, focusing on molecular mechanisms [1]. It is not a new study with patients and not a meta-analysis: the authors organized scattered laboratory and clinical data. They explained how exosomes “talk” to the follicle — where the mechanism is confirmed and where it is still a hypothesis [1].

How exosomes influence the hair follicle: preclinical data

Exosomes are tiny vesicles (30–150 nm) that cells use to exchange information; they contain proteins, lipids, RNA, and even DNA [1]. Long dismissed as cellular “garbage,” they are now considered key mediators of intercellular communication [1].

Key nuance: the “payload” depends on the source cell — exosomes from different sources differ in microRNAs, proteins, and other molecules, and thus in properties [1]. That is why studies specify the source: adipose tissue stem cells, umbilical cord blood, amniotic membrane, dermal papilla cells, or platelet-rich plasma [1].

• Wnt/β-catenin — a gas pedal for growth

This pathway moves the follicle from dormancy into growth and supports stem cell activity [1]. Androgens suppress it from several directions: via the DHT–PGD2–CXXC5 axis and via GSK-3β activation, which promotes β-catenin breakdown [1]. Exosomes can support this pathway — but each “works” with its own microRNA set: dermal papilla cell spheroid exosomes carry miR-218-5p, which suppresses the Wnt inhibitor SFRP2 [1]; umbilical cord stem cell exosomes are rich in miR-21-5p and let-7b-5p, which enhance pathway components (Cyclin D1, LEF1) [1].

In the lab, adipose tissue stem cell exosomes stimulated proliferation and migration of dermal papilla cells (DPC) and reduced apoptosis in vitro [1]; amniotic cell exosomes accelerated hair growth in mice with an AGA model [1]. Caveat: some experiments used standard mouse models without androgen induction of alopecia — those results cannot be automatically transferred to human AGA [1].

• Shh — the second ignition key

The Sonic Hedgehog pathway works alongside Wnt and governs follicle formation and cycling [1]. In AGA, its activity is reduced, partly due to microRNA miR-22-3p [1]. Evidence that exosomes act on Shh specifically in AGA is limited; so far, DPC exosomes have been shown to activate the Wnt and Shh pathways simultaneously in mice [1].

• TGF-β/Smad — the brake that exosomes can release

In AGA, TGF-β1 and TGF-β2 levels rise, which can trigger apoptosis of hair matrix cells, slow their proliferation, and hasten the transition to catagen [1]. Exosomes deliver microRNAs that act on this cascade: miR-122-5p targeting Smad3, plus miR-574-3p and miR-125a-5p targeting Smad2 — all found in adipose tissue stem cell exosomes [1]. In experimental models, this restored follicle activity and stimulated hair growth in mice with AGA [1].

• PI3K/AKT and MAPK — fuel and reactivation

Umbilical cord stem cell exosomes activate PI3K/AKT, increasing DPC proliferative potential, and can reactivate the MAPK pathway, which is weakened in AGA, supporting cell proliferation and stem cell activity [1]. This combined action across several mechanisms makes exosomes an interesting target for further study.

What clinical studies show

The review includes four clinical studies [1]. The injection approach was studied by Ersan and coauthors: 30 men with AGA received a single 3 mL injection of exosomes from foreskin mesenchymal stromal cells (2 mL into the frontal zone, 1 mL into the crown) [2]. After 12 weeks, hair density increased by 7.3 hairs/cm² (p<0.05), and patients rated the result highly [2].

Three studies combined microneedling with topical adipose tissue stem cell exosomes. Park and coauthors (retrospective analysis, 39 patients: 27 men, 12 women) treated weekly for 12 weeks: density grew by 24.9 hairs/cm², shaft thickness by 8.8 µm (p<0.001) [3]. Wan and coauthors (16 men, a single procedure) documented a gain of 35 hairs/cm² at 12 months; 87% were satisfied or very satisfied [4]. Lee and coauthors (30 patients: 14 men, 16 women; weekly for 3 months, then every 3 weeks for another 3 months) reported +8.11 hairs/cm² (p<0.001) at 24 weeks, with improved photographic assessments [5].

No serious adverse events were registered in any of the four studies [2–5]. Reactions were mild: discomfort from microneedling punctures [3], scalp soreness and irritation resolving within 48 hours [4]; Ersan's team reported no side effects [2]. But no serious adverse events in small, short studies do not prove long-term safety.

Limitations

The authors list the weak points: scarce clinical data, small samples, no control groups, short follow-up [1]. Products differ in exosome source, isolation methods, storage conditions, and composition — they cannot be compared directly [1]. Standardized dosing and administration protocols do not yet exist [1]. Most importantly: in microneedling studies, the contribution of exosomes cannot be separated from the effect of the procedure itself [1].

What this means for practice

For the practitioner, this review is a tool for critically evaluating publications and commercial offers around exosome therapy. Worth asking: which cells the exosomes came from, how the product was characterized, what makes up its payload, how and how often it was administered, whether there was a control group, and how long patients were followed — these parameters determine how comparable results are across studies [1].

Exosomes remain a promising cell-free direction: in preclinical models they acted on signaling pathways involved in hair growth and follicle cycling, and early clinical observations showed density and thickness gains with good tolerability [1]. None of these protocols can yet be considered a routine standard of care for AGA: randomized controlled trials with larger samples, standardized products, comparable administration methods, and long-term follow-up are still needed. For now, exosome therapy for AGA is a promising direction with early encouraging clinical signals — not an established method with proven long-term efficacy [1].

References

1. Chen Y., Chen S., Ding W. et al. Progress in the application of exosomes in androgenetic alopecia: focusing on molecular mechanisms. Int J Nanomedicine 2026;21:619230.
2. Ersan M., Ozer E., Akin O. et al. Effectiveness of exosome treatment in androgenetic alopecia: outcomes of a prospective study. Aesthetic Plast Surg 2024; 48(21): 4262–4271.
3. Park B.S., Choi H.I., Huh G., Kim W.S. Effects of exosome from adipose-derived stem cell on hair loss: a retrospective analysis of 39 patients. J Cosmet Dermatol. 2022; 21(5): 2282–2284.
4. Wan J., Kim S.B., Cartier H. et al. A prospective study of exosome therapy for androgenetic alopecia. Aesthetic Plast Surg 2025; 49(11): 3151–3156.
5. Lee E., Choi M.S., Cho B.S. et al. The efficacy of adipose stem cell-derived exosomes in hair regeneration based on a preclinical and clinical study. Int J Dermatol 2024; 63(9): 1212–1220.